Oxymetazoline: A Comprehensive Pharmacological and Clinical Review

1. Introduction to Oxymetazoline

Overview, Historical Context, and Therapeutic Class

Oxymetazoline is an imidazole derivative that functions as a potent, direct-acting sympathomimetic agent. Its primary pharmacological activity is as an alpha (α)-adrenergic agonist.[1] Developed in 1961 by Wolfgang Fruhstorfer and Helmut Müller-Calgan at E. Merck Darmstadt, oxymetazoline was derived from xylometazoline.[2] Therapeutically, it is classified as a vasoconstrictor and topical decongestant, initially recognized for its utility in alleviating nasal congestion.[2]

The clinical applications of oxymetazoline have expanded considerably since its introduction. It is widely available in over-the-counter (OTC) intranasal sprays for the management of nasal congestion. Furthermore, its therapeutic scope now includes prescription formulations such as topical creams for persistent facial erythema associated with rosacea and ophthalmic solutions for acquired blepharoptosis (drooping eyelids) and nonspecific ocular redness.[1] Oxymetazoline is also a constituent of a combination product, Kovanaze, used to achieve regional anesthesia in certain dental procedures.[1]

The brand Afrin, a well-known oxymetazoline nasal spray, was first marketed as a prescription medication in 1966. Its success led to its transition to an over-the-counter product in 1975.[2] This long history of use, coupled with recent FDA approvals for novel indications—Rhofade for rosacea in 2017 and Upneeq for blepharoptosis in 2020—underscores the sustained therapeutic relevance and versatility of oxymetazoline.[1]

The evolution of oxymetazoline's applications from a general nasal decongestant to highly specialized ophthalmic and dermatological treatments illustrates a significant trend in pharmaceutical development: the repurposing of established molecules with well-characterized mechanisms for new therapeutic targets. This is often achieved through localized delivery systems and a refined understanding of receptor distribution and function. Oxymetazoline's core mechanism, α-adrenergic agonism leading to vasoconstriction, is relatively straightforward.[1] Initial applications, such as nasal sprays, often resulted in some systemic absorption.[2] However, later developments, including Rhofade topical cream and Upneeq ophthalmic solution, have focused on precise, localized delivery to the face and specific eye muscles, respectively.[1] This targeted approach aims to maximize local therapeutic effects while minimizing systemic exposure and associated adverse events. Such a strategy represents a common pathway in drug development, leveraging known safety and efficacy profiles to address new clinical needs, often with lower risk and shorter development timelines than de novo drug discovery.

The enduring presence of oxymetazoline in the therapeutic armamentarium, from its inception in the 1960s to recent FDA approvals and ongoing clinical investigations [10], speaks to its adaptability and perceived value. This longevity, however, also implies that early research may not align with contemporary rigorous scientific standards, and the long-term effects in its newer, specialized applications are still under evaluation. For instance, while the vasoconstrictive properties are beneficial across its varied uses, the potential for rebound effects, long-recognized with nasal formulations [2], is a consideration that extends to its ophthalmic applications, indicating that the fundamental pharmacology presents consistent challenges that necessitate careful management regardless of the delivery route or indication.

2. Chemical and Physicochemical Properties

Oxymetazoline is classified as a small molecule drug.[1] It is an imidazole derivative, and its chemical structure and properties are crucial for its pharmacological activity and formulation characteristics.

Identification

• Drug Name: Oxymetazoline [User Query]
• DrugBank ID: DB00935 [User Query]
• CAS Number (Base): 1491-59-4 [13]
• CAS Number (Hydrochloride Salt): 2315-02-8 [14]

Molecular Structure

• IUPAC Name (Base): 6-tert-butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol.[15] The hydrochloride salt is 6-tert-butyl-3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2,4-dimethylphenol hydrochloride.[14]
• SMILES (Base): Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C [13]
• InChI (Base): InChI=1S/C16H24N2O/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14/h8,19H,6-7,9H2,1-5H3,(H,17,18) [13]
• InChIKey (Base): WYWIFABBXFUGLM-UHFFFAOYSA-N [13]

Molecular Formula and Weight

• Molecular Formula (Base): C16​H24​N2​O [13]
• Molecular Weight (Base): 260.37 g/mol (PubChem CID 4636); [13] reports 260.19 g/mol.
• Molecular Formula (Hydrochloride): C16​H25​ClN2​O [14]
• Molecular Weight (Hydrochloride): Average: 296.836 g/mol; Monoisotopic: 296.165541139 g/mol.[14]

Physical Characteristics

The hydrochloride salt of oxymetazoline typically appears as a white or almost white, hygroscopic crystalline powder with a bitter taste.[4] Key physicochemical parameters are summarized in Table 1.

The lipophilicity of oxymetazoline, as indicated by its LogP value of approximately 3 to 3.7, is a significant determinant of its pharmacokinetic behavior and therapeutic utility.[13] This property facilitates rapid absorption across mucosal surfaces, such as the nasal and ocular epithelia, enabling prompt local action.[1] However, this lipophilicity also creates a potential for systemic absorption, which can lead to undesired systemic side effects, particularly if the drug is used excessively or in patient populations with compromised metabolic or excretory functions.[2] This balance between achieving effective local concentrations and minimizing systemic exposure is a critical consideration in the formulation design and recommended usage guidelines for oxymetazoline products.

Stability and Storage Conditions

Storage conditions for oxymetazoline products vary depending on the specific formulation and intended use:

• Nasal Solutions (e.g., Afrin): Generally stored at room temperature, between 20°C to 25°C (68°F to 77°F), avoiding temperatures below 0°C (freezing) and above 40°C. Protection from light is also recommended.[17] The product is not considered flammable or explosive under normal conditions.[22]
• Ophthalmic Solution (General): Typically stored at 15°C to 30°C. Aluminum containers should be avoided for storage.[17]
• Upneeq (0.1% Ophthalmic Solution): Stored at room temperature, 20°C to 25°C (68°F to 77°F), in its child-resistant foil pouch until use. It should be protected from excessive heat, and single-use vials must be discarded immediately after administration.[23]
• Rhofade (1% Topical Cream): Stored at room temperature, 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). Freezing should be avoided.[25]
• Kovanaze (Nasal Spray for Dental Anesthesia): Requires refrigeration, stored between 2°C and 8°C (36°F and 46°F). Short excursions between 0°C and 15°C (32°F and 59°F) are permitted. If left at room temperature for more than 5 days, it should not be used.[26]

The diversity in storage requirements across different oxymetazoline formulations, such as the need for refrigeration for Kovanaze versus room temperature stability for most other products, underscores the influence of formulation excipients, drug concentration, and the specific stability and sterility demands for each route of administration.[17] For example, Kovanaze is a combination product containing tetracaine, whose stability might necessitate refrigerated storage. Similarly, preservative systems in multi-dose nasal sprays versus the preservative-free nature of single-use Upneeq vials can impact stability and storage. These variations have direct practical consequences for pharmaceutical supply chains, pharmacy storage protocols, and patient handling and convenience.

Table 1: Key Chemical and Physicochemical Properties of Oxymetazoline

Property	Value (Oxymetazoline Base)	Value (Oxymetazoline HCl)	Source(s)
CAS Number	1491-59-4	2315-02-8	User Query, 13
DrugBank ID	DB00935	DB00935 (references base)	User Query
Molecular Formula	C16​H24​N2​O	C16​H25​ClN2​O	13
Molecular Weight (g/mol)	260.37 (PubChem CID 4636)	Avg: 296.836	13
IUPAC Name	6-tert-butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol	6-tert-butyl-3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2,4-dimethylphenol hydrochloride	14
SMILES	Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C	Cl.CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C	13
InChI	1S/C16H24N2O/... (abbreviated)	1S/C16H24N2O.ClH/... (abbreviated)	13
InChIKey	WYWIFABBXFUGLM-UHFFFAOYSA-N	BEEDODBODQVSIM-UHFFFAOYSA-N	13
Appearance	-	White or almost white, hygroscopic crystalline powder	4
Water Solubility	-	0.0515 mg/mL (ALOGPS)	14
pKa (Strongest Acidic)	-	10.91 (Phenol, Chemaxon)	14
pKa (Strongest Basic)	-	10.15 (Imidazoline, Chemaxon)	14
LogP	3.36 (XLogP)	3.7 (ALOGPS); 3.03 (Chemaxon)	13
Hydrogen Bond Acceptors	2	3 (Chemaxon)	13
Hydrogen Bond Donors	2	2 (Chemaxon)	13
Rotatable Bonds	3	3 (Chemaxon)	13
Topological Polar Surface Area (TPSA)	44.62 A˚2	44.62 A˚2 (Chemaxon)	13
Lipinski's Rule Compliance	Yes (0 rules broken)	Yes (Chemaxon)	13

3. Pharmacology

3.1. Mechanism of Action

Oxymetazoline is a direct-acting sympathomimetic amine that exerts its effects primarily through agonism at α-adrenergic receptors. It is characterized as a selective agonist at α1​-adrenergic receptors and a partial agonist at α2​-adrenergic receptors.[1]

Vasoconstriction: The principal pharmacological action of oxymetazoline is vasoconstriction, which results from its binding to and activation of α1​-adrenergic receptors. These receptors are abundantly expressed in the vascular smooth muscle of arterioles.[1] When applied locally, oxymetazoline also induces vasoconstriction via its effects on endothelial postsynaptic α2​-receptors.[2] This vasoconstrictive effect is the basis for its therapeutic applications across various conditions.

Nasal Decongestion: In the nasal mucosa, the activation of α-adrenergic receptors by oxymetazoline leads to constriction of dilated arterioles. This reduces local blood flow, decreases tissue edema, and shrinks swollen nasal membranes. Consequently, the diameter of the nasal airway lumen increases, fluid exudation from postcapillary venules is diminished, and nasal airflow resistance is reduced, providing relief from nasal congestion.[1] Studies have indicated that oxymetazoline can decrease nasal airway resistance by up to 35.7% and reduce nasal mucosal blood flow by as much as 50%.[2]

Facial Erythema of Rosacea: For the treatment of persistent facial erythema associated with rosacea, topical oxymetazoline (Rhofade) acts by stimulating α1A​-adrenoceptors located in the dermal microvasculature. This targeted vasoconstriction reduces blood flow to the superficial vessels of the skin, thereby diminishing the visible redness characteristic of rosacea.[1]

Acquired Blepharoptosis (Ptosis): In the management of acquired blepharoptosis, ophthalmic oxymetazoline (Upneeq) is thought to exert its effect by stimulating α-adrenergic receptors (both α1​ and α2​) on Müller's muscle (also known as the superior tarsal muscle). Müller's muscle is a smooth muscle innervated by the sympathetic nervous system that contributes to upper eyelid elevation. Agonism at these receptors causes contraction of Müller's muscle, resulting in a temporary lift of the upper eyelid.[1]

Ocular Redness: When applied to the eye for redness relief, oxymetazoline causes vasoconstriction of the conjunctival arterioles by activating α-adrenergic receptors. This action reduces blood flow in these vessels, leading to a decrease in conjunctival congestion and an improvement in eye appearance.[13]

Dental Anesthesia (Kovanaze - in combination with Tetracaine): In the Kovanaze intranasal spray formulation, oxymetazoline serves as a vasoconstrictor. Its role is to reduce local blood flow in the nasal and maxillary tissues. This localized vasoconstriction is critical because it slows the systemic absorption of the co-administered local anesthetic, tetracaine. By limiting the washout of tetracaine from the target site, oxymetazoline prolongs its duration of action and enhances the depth and efficacy of regional dental anesthesia.[4]

Potential Anti-inflammatory/Antioxidant Effects: An early in vitro investigation suggested that oxymetazoline might possess antioxidant properties. The study demonstrated inhibition of microsomal lipid peroxidation and hydroxyl radical scavenging activity, implying a potential beneficial role against oxidative stress, which is implicated in inflammatory tissue damage.[1] However, the clinical relevance of this finding remains to be fully elucidated.

3.2. Pharmacodynamics (Receptor Affinity and Selectivity)

Oxymetazoline interacts with both α1​- and α2​-adrenoceptors. These receptors are G-protein coupled receptors; α1​-adrenoceptors are typically coupled to Gq​ proteins, leading to increased intracellular calcium, while α2​-adrenoceptors are usually coupled to Gi​ proteins, inhibiting adenylyl cyclase and reducing cyclic AMP levels.[1]

The selectivity profile of oxymetazoline for various adrenergic receptor subtypes has been investigated, with some variations reported in the literature:

• One radioligand competition study indicated that oxymetazoline exhibits a higher affinity for α1A​-adrenoceptors compared to α2B​-adrenoceptors, yet it demonstrated higher potency at α2B​-adrenoceptors.[1]
• Another study proposed a selectivity order of α2A​>α1A​≥α2B​>α1D​≥α2C​>>α1B​.[2] This order, however, is not universally accepted.
• A separate investigation reported specific selectivity ratios for α2​-adrenergic receptor subtypes: 200-fold for α2A​ versus α2B​, 7.1-fold for α2A​ versus α2C​, and 28.2-fold for α2B​ versus α2C​.[2] Oxymetazoline demonstrates little to no significant activity at β-adrenergic receptors.[2]

Furthermore, detailed receptor binding data indicate that oxymetazoline also possesses agonist activity at several 5-hydroxytryptamine (serotonin) receptor subtypes, including 5-HT1A​, 5-HT1B​, and 5-HT1D​ receptors, and acts as a partial agonist at 5-HT2C​ receptors.[29] This broader receptor interaction profile, extending beyond just α-adrenergic receptors, may contribute to its overall pharmacological effects and potentially to some of its side effects, particularly if significant systemic absorption occurs. The commonly cited "selectivity" for α1​ or α2​ receptors might be relative and context-dependent (e.g., varying with tissue type or receptor density) rather than absolute. This complex receptor engagement could explain some nuanced or off-target responses and may offer avenues for future research or understanding idiosyncratic reactions.

3.3. Pharmacokinetics (Absorption, Distribution, Metabolism, Excretion across formulations)

General Absorption: Oxymetazoline is readily absorbed following oral administration, although this is not a therapeutic route.[2] Systemic effects resulting from absorption after topical application (e.g., intranasal) can persist for up to 7 hours.[2] Its lipophilic nature facilitates rapid absorption through mucosal membranes and can lead to entry into systemic circulation.[19]

Nasal Administration (Decongestant):

• Absorption: Rapidly absorbed from intranasal tissues.[18] The onset of local vasoconstriction is typically observed within 5–10 minutes.[17]
• Duration of Action: Local vasoconstrictive effects generally persist for 5–6 hours, with a gradual decline over the subsequent 6 hours.[17] Some studies report effects lasting up to 12 hours.[1]

Topical Cream (Rhofade 1% - for Rosacea):

• Systemic Absorption: Following the first topical application of a 1% cream, the mean peak plasma concentration (Cmax​) was 60.5±53.9 pg/mL, and the area under the plasma concentration-time curve from 0 to 24 hours (AUC0−24hr​) was 895±798 pg⋅hr/mL. After 28 days of once-daily application, the mean Cmax​ was 66.4±67.1 pg/mL and AUC0−24hr​ was 1050±992 pg⋅hr/mL. With twice-daily applications for 28 days, mean Cmax​ was 68.8±61.1 pg/mL and AUC0−24hr​ was 1530±922 pg⋅hr/mL.[1] These data suggest low systemic exposure with typical dermatological use.

Ophthalmic Solution (Upneeq 0.1% - for Ptosis):

• Systemic Absorption: After a single drop of 0.1% oxymetazoline ophthalmic solution in healthy adults, the mean Cmax​ was 30.5±12.7 pg/mL, and the area under the concentration-time curve to infinity (AUCinf​) was 468±214 pg⋅hr/mL. The median time to peak concentration (Tmax​) was 2 hours (range: 0.5 to 12 hours).[1]
• Onset of Action: Rapid, with eyelid elevation observed as early as 5 minutes post-instillation.[27]
• Duration of Action: Sustained eyelid elevation for at least 6–8 hours.[5]

Ophthalmic Solution (General Redness Relief - e.g., Visine L.R. 0.025%):

• Onset of Action: Local vasoconstriction typically occurs within minutes.[17]
• Duration of Action: Effects persist for up to 6 hours.[17]

Nasal Spray (Kovanaze - Dental Anesthesia, with Tetracaine):

• Systemic Absorption (Oxymetazoline): Following administration of a 0.6 mL combination product, Cmax​ of oxymetazoline was reached in approximately 10 minutes. The mean Cmax​ was 1.78 ng/mL, and the AUC0−inf​ was 4.24 ng⋅h/mL, with a median Tmax​ of 5 minutes.[1]
• Pharmacokinetics of Tetracaine: Tetracaine has a very short half-life and is often undetectable systemically after Kovanaze administration.[28]

Distribution:

• Information on the volume of distribution is limited.[1]
• Protein Binding: In vitro, oxymetazoline is 56.7% to 57.5% bound to human plasma proteins.[1]
• Oxymetazoline can cross the blood-brain barrier, particularly at high doses or with chronic use, which may contribute to central nervous system effects.[18]

Metabolism:

• In vitro studies indicate that oxymetazoline undergoes minimal metabolism by human liver enzymes (Cytochrome P450 system), with primary products being mono-oxygenated and dehydrogenated metabolites.[1]
• Approximately 95.9% of an oxymetazoline dose remained as the unchanged parent compound after a 120-minute incubation with human liver microsomes, suggesting a low rate of hepatic metabolism.[1]
• At high concentrations (e.g., 50 μM), CYP2C19 has been implicated in the oxidation of oxymetazoline following intranasal administration. UDP-glucuronosyltransferase 1A9 (UGT1A9) is also involved in its metabolism.[1] However, human metabolites have not been fully characterized.
• One identified metabolite is Oxymetazoline metabolite M2 (6-(1,1-Dimethylethyl)-3-(1H-imidazol-2-ylmethyl)-2,4-dimethylphenol).[16] The minimal metabolism of oxymetazoline implies a reduced likelihood of significant metabolic drug-drug interactions involving the parent drug via the CYP450 system, provided these enzyme pathways are not saturated. However, the identified involvement of CYP2C19 and UGT1A9 means that potent inhibitors or inducers of these specific enzymes could theoretically influence oxymetazoline clearance. This becomes more pertinent if systemic exposure to oxymetazoline is substantial, such as with overuse or with formulations like Kovanaze that achieve higher peak plasma concentrations.

Excretion:

• The elimination half-life (t1/2​) of oxymetazoline in humans is generally reported as 5–8 hours for nasal administration.[2] For Upneeq ophthalmic solution, the mean terminal t1/2​ is approximately 8.3 hours (range: 5.6 to 13.9 hours).[24] For the oxymetazoline component in Kovanaze intranasal spray, a shorter half-life of approximately 2 hours has been reported.[28]
• Oxymetazoline is excreted largely unchanged, with about 30% of an absorbed dose eliminated via the kidneys and 10% via feces.[2] It is primarily excreted in the urine as both unchanged drug and its metabolites.[18]

The notable variation in reported elimination half-lives (e.g., ~2 hours for Kovanaze, 5-8 hours for general nasal use, ~8.3 hours for Upneeq) likely reflects differences in formulation characteristics, resulting absorption rates, the extent of systemic exposure achieved, and potentially the sensitivity of analytical methodologies employed in various studies. This variability is crucial for accurately predicting the duration of systemic effects and for determining appropriate dosing intervals for the different oxymetazoline-containing products. For instance, the higher Cmax​ observed with Kovanaze (1.78 ng/mL) compared to Upneeq (30.5 pg/mL) or Rhofade (60−70 pg/mL), despite Kovanaze's shorter reported t1/2​ for oxymetazoline, might indicate more rapid absorption and distribution phases, or perhaps differential engagement of metabolic or elimination pathways based on the achieved plasma concentrations.[1]

4. Clinical Applications and Efficacy

Oxymetazoline is utilized in various formulations to treat a range of conditions, leveraging its vasoconstrictive and sympathomimetic properties.

4.1. Nasal Decongestion

• Marketed Products: Afrin®, Vicks Sinex®, Dristan 12-hour Nasal Spray, Nostrilla, Sinex Long-acting, Sudafed OM, among others.[1]
• Indication: Provides temporary relief of nasal and sinus congestion associated with the common cold, hay fever (allergic rhinitis), and other upper respiratory allergies.[1] It is also used to manage epistaxis (nosebleeds).[2]
• Formulation: Commonly available as a 0.05% oxymetazoline hydrochloride nasal spray.[30] Lower concentration formulations (e.g., 0.025%) are also available, particularly for pediatric use.[20]
• Efficacy:
• Oxymetazoline nasal spray offers rapid relief, with an onset of action typically within 5-10 minutes.[17]
• A single dose can provide a duration of effect lasting up to 12 hours.[1] A pooled analysis of two randomized, double-blind, vehicle-controlled studies involving patients with acute coryzal rhinitis (Study 1, n=67; Study 2, n=61) demonstrated that 0.05% oxymetazoline nasal spray provided statistically significant and clinically meaningful relief of subjective nasal congestion and objectively improved nasal airflow (measured by anterior rhinomanometry) for up to 12 hours compared to vehicle.[1]
• A study conducted in 30 healthy adult subjects evaluated the use of 0.05% oxymetazoline nasal spray administered three times daily for four weeks. The results showed no significant development of nasal blockage or impaired decongestant response (tachyphylaxis) when compared to a placebo group. A significant decongestant effect was consistently observed at each clinic visit throughout the study.[1] It is important to contextualize this finding, as general clinical guidance strongly warns against prolonged use (beyond 3-7 days) due to the risk of rebound congestion, particularly in individuals with active nasal inflammation or congestion.[2] The discrepancy may arise because the study population consisted of "normal subjects" whose nasal physiology might differ from those with underlying inflammatory conditions leading to congestion. The pathophysiology of rebound congestion might be more readily induced or exacerbated in inflamed or already congested nasal mucosa.
• Administration: The typical adult dosage is 2-3 sprays into each nostril every 10-12 hours, not to exceed two doses in any 24-hour period. To minimize the risk of rebound congestion (rhinitis medicamentosa), use is generally recommended for a maximum of 3 consecutive days.[11]

4.2. Persistent Facial Erythema of Rosacea

• Marketed Product: Rhofade®.[1]
• Indication: Topical treatment of persistent facial erythema (redness) associated with rosacea in adult patients.[1]
• Formulation: 1% oxymetazoline hydrochloride topical cream.[6]
• Efficacy:
• A phase II, before-after clinical trial involving 15 patients with mild to moderate rosacea treated with 1% oxymetazoline cream twice daily for 4 weeks reported significant decreases in both Clinician's Erythema Assessment (CEA) and Patient's Self-Assessment (PSA) scores at 2 and 4 weeks of treatment (p=0.001 for both). Objective measurement using a Mexameter also showed a significant reduction in the erythema index. Capillaroscopic examination revealed a decrease in telangiectasia and a reduction in the reddish background of the skin.[1]
• According to information for patients from the Rhofade website, clinical trial data showed that on Day 29 of treatment, 12% to 18% of adult patients using Rhofade® cream experienced a reduction in facial redness that lasted through 12 hours (assessed at 3, 6, 9, and 12 hours post-application), compared to 5% to 9% of patients using the vehicle cream.[1]
• A review of phase III trials indicated that oxymetazoline met the primary efficacy outcome, defined as at least a 2-grade decrease from baseline on both CEA and Subject Self-Assessment (SSA) scales, compared to the vehicle control.[41]
• Administration: A pea-sized amount of the cream is applied once daily in a thin layer to cover the entire face (forehead, nose, each cheek, and chin).[25]

4.3. Acquired Blepharoptosis

• Marketed Product: Upneeq®.[1]
• Indication: Treatment of acquired blepharoptosis (low-lying eyelids) in adults. Upneeq was the first FDA-approved pharmacological treatment for this condition.[1]
• Formulation: 0.1% oxymetazoline hydrochloride ophthalmic solution, supplied in preservative-free, single-use vials.[5]
• Efficacy:
• Pooled data from two phase 3 randomized, placebo-controlled trials (total N=304; 203 treated with Upneeq, 101 with vehicle) demonstrated a rapid onset of action.
• On Day 1, the mean change from baseline in Marginal Reflex Distance 1 (MRD-1, a measure of upper eyelid height) at 5 minutes post-instillation was 0.59±0.72 mm for Upneeq versus 0.20±0.57 mm for vehicle (p<0.001). At 15 minutes post-instillation on Day 1, the mean change was 0.93±0.81 mm for Upneeq versus 0.32±0.64 mm for vehicle (p<0.001).
• Similar significant improvements in MRD-1 were observed at 5 and 15 minutes post-instillation on Day 14 (mean change at 15 min: 1.11±0.92 mm for Upneeq vs 0.41±0.83 mm for vehicle; p<0.05) and Day 42 (mean change at 15 min: 1.04±0.91 mm for Upneeq vs 0.47±0.93 mm for vehicle; p<0.005).
• Significant improvements in MRD-1 compared to vehicle were also maintained at 2-hour and 6-hour post-instillation time points on Days 1 and 14 (p<0.001).[1] The average upper eyelid lift observed in clinical studies was approximately 1 mm.[43]
• Upneeq has also been shown to significantly improve superior visual field deficits associated with ptosis.[27]
• The duration of effect is reported to be at least 6–8 hours after a single daily dose.[5] Efficacy was maintained at 42 days of treatment.[7]
• Clinical trial data indicate that 87.8% of patients experienced some degree of improvement in eyelid lift, and 40.8% achieved at least a 50% improvement on Day 14 (measured 2 hours post-application).[43] Another source states 84% of patients had some improvement.[31]
• Administration: One drop is instilled into one or both ptotic eyes once daily.[5]

The ophthalmic applications of oxymetazoline, including Upneeq for ptosis, Visine L.R. for ocular redness, and its investigational use for presbyopia, demonstrate a sophisticated leveraging of its fundamental α-adrenergic agonist properties. These varied uses target different ocular structures—Müller's muscle for eyelid elevation, conjunctival blood vessels for redness reduction, and potentially pupillary or ciliary muscles for presbyopia correction—all of which possess adrenergic innervation.[1] This ability to address multiple, distinct ophthalmological conditions with a single active pharmaceutical ingredient, primarily through adjustments in concentration and precise delivery mechanisms, highlights advancements in ocular pharmacology and formulation science. It also implies that careful targeting is necessary to avoid off-target effects, such as unintended redness reduction during ptosis treatment or vice-versa, if drug concentrations or delivery were less optimized.

4.4. Ocular Redness Relief

• Marketed Product: Visine L.R.®.[2]
• Indication: Symptomatic relief of redness of the eye due to minor eye irritations.[2]
• Formulation: Typically a 0.025% oxymetazoline hydrochloride ophthalmic solution.[47]
• Efficacy:
• A double-blind study involving 141 patients compared 0.025% oxymetazoline ophthalmic solution with its vehicle for the treatment of allergic and non-infectious conjunctivitis. A marked difference in response was noted at the first evaluation. By the tenth day of treatment, the total improvement in hyperemia was 95% in the oxymetazoline group compared to 54% in the placebo group.[30]
• A randomized controlled trial (NCT04831047, N=114) using a higher concentration of oxymetazoline (0.1%, the same as Upneeq) found that it significantly decreased general eye redness (mean change -2.6 ± 4.4 vs -0.5 ± 2.3 for placebo, p=0.002) and improved patient-perceived eye appearance in individuals without severe ptosis.[12] While this study demonstrates an effect on eye redness, it was not specifically focused on allergic conjunctivitis.
• Administration (Visine L.R.): For adults and children 6 years of age and older, 1 to 2 drops are instilled in the affected eye(s) every 6 hours as needed, or as directed by a physician.[47]

4.5. Regional Dental Anesthesia

• Marketed Product: Kovanaze® (in combination with Tetracaine HCl).[1]
• Indication: Provides regional anesthesia for restorative dental procedures on maxillary teeth (specifically teeth #4-13 in the permanent dentition and teeth A-J in the primary dentition) in adults and children who weigh 40 kg or more.[1]
• Formulation: An intranasal spray, with each 0.2 mL spray delivering 6 mg of tetracaine hydrochloride and 0.1 mg of oxymetazoline hydrochloride.[26]
• Efficacy:
• Clinical studies have reported a success rate of 83% to 90% in achieving sufficient local anesthesia to perform routine dental restorative procedures on maxillary premolars, canines, and incisors without the need for rescue injectable anesthesia.[28]
• In phase 3 randomized controlled trials in adults:
• Study 1: Kovanaze demonstrated an 84% success rate compared to 27% for both tetracaine HCl alone and placebo groups.[26]
• Study 2: Kovanaze showed an 88% success rate versus 28% for the placebo group.[26] Success rates were generally lower for procedures on the second premolar teeth compared to more anterior teeth.
• In a phase 3 study involving pediatric patients, those weighing 40 kg or more experienced a 90% success rate with Kovanaze, compared to 40% with placebo.[26]
• The oxymetazoline component is crucial for the anesthetic success of Kovanaze. Its vasoconstrictive action reduces local blood flow, thereby slowing the systemic absorption of tetracaine and prolonging its local anesthetic effect at the nerve endings.[4] This synergistic combination, where oxymetazoline acts as an adjuvant rather than the primary therapeutic agent, is a key pharmacological principle. It is analogous to the use of epinephrine with injectable local anesthetics to prolong their duration of action. The innovation of Kovanaze lies in applying this principle to a needle-free, intranasal delivery system for maxillary dental anesthesia, potentially inspiring similar approaches for other drugs requiring enhanced localized effects in highly vascularized areas accessible via topical routes.
• Administration: Two sprays (0.2 mL each) are administered 4 to 5 minutes apart into the nostril ipsilateral to the maxillary tooth on which the dental procedure is to be performed. The dental procedure is typically initiated 10 minutes after the second spray. If adequate anesthesia has not been achieved 10 minutes after the second spray, one additional spray (0.2 mL) may be administered.[26]

4.6. Investigational and Other Uses

• Presbyopia: Oxymetazoline, as part of investigational formulations (AGN-190584, AGN-199201), has completed Phase 2 clinical trials for the treatment of presbyopia.[10] This suggests exploration of its effects on pupillary dynamics or ciliary muscle function.
• Nasal Intubation and ENT Surgery: Oxymetazoline has been used off-label during nasal intubation procedures and in ear, nose, and throat (ENT) surgeries to improve visualization of the airway and to minimize post-operative bleeding due to its vasoconstrictive effects.[1]
• Sleep Apnea: There is ongoing research into the potential use of oxymetazoline nasal spray, often in conjunction with other treatments, to help improve symptoms in patients with mild obstructive sleep apnea.[11]
• Pulpal Hemostasis in Dentistry: Emerging research indicates that an over-the-counter nasal solution containing oxymetazoline (NS-OXY, which also contains benzalkonium chloride - BKC) shows potential as a hemostatic agent for dental pulp management. This is attributed to the vasoconstrictive properties of oxymetazoline and the antimicrobial effects of BKC.[51]

5. Comprehensive Safety Profile

The safety profile of oxymetazoline varies depending on its formulation, route of administration, concentration, and the specific patient population.

5.1. Adverse Effects (by formulation)

Nasal Formulations (e.g., Afrin, general decongestants):

• Common Local Effects: Temporary burning, stinging, or dryness inside the nose, sneezing, and an increase in nasal discharge or runny nose are frequently reported shortly after administration.[11]
• Rebound Congestion (Rhinitis Medicamentosa): Prolonged use, typically defined as more than 3 to 7 days, can lead to rebound nasal congestion. This condition is characterized by a worsening of nasal obstruction as the effects of the drug wear off, often leading to a cycle of increased use and dependence.[2]
• Systemic Effects (from absorption): Headache, dizziness, nausea, nervousness, insomnia, tremors, unusual sweating, weakness, palpitations (slow, fast, or pounding heartbeat), chest pain, and elevations in blood pressure can occur due to systemic absorption.[21]
• Epistaxis (Nosebleeds): Can occur, particularly if the nasal passages are already dry.[2]
• Serious Allergic Reactions (Rare): Symptoms may include rash, itching, hives, swelling (especially of the face, tongue, or throat), breathing difficulties, and severe dizziness.[32]

Ophthalmic Formulations:

• Upneeq (0.1% for Ptosis): The most common adverse events, occurring in 1-5% of patients, include punctate keratitis, conjunctival hyperemia (eye redness), dry eye, blurred vision, instillation site pain, eye irritation, and headache.[9] There is a potential for rebound hyperemia, development of dependence, or diminished efficacy over time with prolonged use.[7] Oxymetazoline ophthalmic solutions may also increase intraocular pressure and pose a risk of angle-closure glaucoma in susceptible individuals.[9]
• Visine L.R. (0.025% for Redness): Overuse may paradoxically increase eye redness.[47] Less common side effects include blurred vision, painful irritation of the cornea, and redness of the sclera or inner eyelids.[56]

Topical Cream (Rhofade 1% for Rosacea):

• The most common adverse reactions (incidence ≥1%) are application site reactions, including dermatitis (2%), worsening of inflammatory lesions of rosacea (1-3%), pruritus (itching, 1-2%), erythema (redness, 1-2%), and pain (1-2%).[11]

Combination Nasal Spray (Kovanaze - Dental Anesthesia):

• Most Common (>10%): Rhinorrhea (runny nose), nasal congestion, nasal discomfort, oropharyngeal pain (sore throat), and increased lacrimation (watery eyes).[26]
• Less Common (≥2%): Intranasal or pharyngeal hypoesthesia (numbness), throat irritation, rhinalgia (nasal pain), sneezing, epistaxis, nasal dryness, headache, dysgeusia (altered taste), sinus headache, dizziness, sensory disturbances, oral discomfort, and transient asymptomatic elevations in systolic blood pressure (≥ 25 mm Hg from baseline) and diastolic blood pressure (≥ 15 mm Hg from baseline) have been reported.[26] Intranasal ulcerations and dysphagia (difficulty swallowing) have also been noted.[26]
• Methemoglobinemia: A rare but serious adverse event associated with Kovanaze, particularly when co-administered with other methemoglobin-inducing agents or in susceptible individuals.[26]

The consistent risk of rebound phenomena, such as nasal congestion with nasal sprays and ocular hyperemia with ophthalmic solutions, across different topical formulations of oxymetazoline is noteworthy.[2] This suggests a common physiological response to prolonged α-adrenergic stimulation on mucosal surfaces. This response likely involves adaptive mechanisms such as receptor desensitization or downregulation, leading to vasodilation and worsening symptoms upon drug withdrawal or development of tachyphylaxis (reduced drug effect over time). This shared characteristic has significant implications for patient education, emphasizing adherence to recommended dosing guidelines and duration of use to maintain efficacy and avoid adverse outcomes.

5.2. Contraindications

• General: Known hypersensitivity to oxymetazoline or any excipients present in the specific formulation is a general contraindication.[17] Sensitivity to the pharmacological effects of adrenergic drugs is also a consideration.[17]
• Kovanaze: In addition to oxymetazoline hypersensitivity, Kovanaze is contraindicated in patients with known hypersensitivity to tetracaine, benzyl alcohol, other ester-type local anesthetics, or para-aminobenzoic acid (PABA) and its derivatives.[26] This is due to tetracaine being an ester local anesthetic, which can be metabolized to PABA, a known allergen for some individuals. This distinguishes Kovanaze's contraindication profile from products containing only oxymetazoline.
• Nasal Formulations (General): Specific contraindications may include acute coronary disease, cardiac asthma, angle-closure glaucoma, rhinitis sicca (dry rhinitis), inflammation or lesions of the skin around the nostrils or on the nasal mucosa, pheochromocytoma, and recent trans-sphenoidal hypophysectomy or other nasal/cranial surgery that may have exposed the dura mater.[18]
• Rhofade: The FDA-approved prescribing information for Rhofade does not list any specific contraindications.[25]
• Upneeq: While no absolute contraindications are listed in its prescribing information, caution is advised in certain patient populations (see Warnings and Precautions).[9]

5.3. Warnings and Precautions

• Cardiovascular Disease: Alpha-adrenergic agonists, including oxymetazoline, can affect blood pressure and cardiac function. Therefore, oxymetazoline should be used with caution in patients with severe, unstable, or uncontrolled cardiovascular conditions such as coronary artery disease, orthostatic hypotension, and uncontrolled hypertension or hypotension.[9] Patients with these conditions should be advised to seek medical care if their symptoms worsen. Kovanaze, in particular, has been associated with transient elevations in blood pressure.[26] The pervasiveness of these cardiovascular warnings across all formulations, including those designed for localized effects like Upneeq and Rhofade, underscores the potential for systemic absorption and the inherent potency of α-adrenergic agonists. This necessitates careful patient selection and monitoring, especially in individuals with pre-existing cardiovascular compromise.
• Potentiation of Vascular Insufficiency: Caution is warranted when using oxymetazoline in patients with conditions characterized by vascular insufficiency, such as cerebral or coronary insufficiency, Raynaud’s phenomenon, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome. Patients should be advised to seek medical attention if signs or symptoms of worsening vascular insufficiency develop.[9]
• Risk of Angle-Closure Glaucoma: Oxymetazoline may increase the risk of precipitating an acute angle-closure glaucoma attack in patients with untreated narrow anterior chamber angles. Patients should be advised to seek immediate medical care if they experience symptoms such as eye pain, blurred vision, or halos around lights.[9]
• Other Pre-existing Conditions: Use with caution in patients with diabetes mellitus, thyroid disorders (particularly hyperthyroidism), and difficulty urinating due to benign prostatic hyperplasia (BPH).[21]
• Methemoglobinemia (Kovanaze): Kovanaze carries a warning for methemoglobinemia, a rare but serious condition. The risk may be increased with concomitant use of methemoglobin-inducing agents or in individuals with certain genetic predispositions.[26]
• Local Irritation/Wounds (Rhofade): Rhofade cream should not be applied to irritated skin or open wounds.[25]
• Contamination of Applicator: To prevent contamination and potential eye injury or infection, the tip of nasal spray or ophthalmic solution containers should not touch the eye, nostril, or any other surface. Nasal spray devices should not be shared among individuals.[21]

5.4. Overdosage: Manifestations and Management

• Nasal/Systemic Overdose: Symptoms of oxymetazoline overdose can result from excessive local use leading to significant systemic absorption or from accidental ingestion. Manifestations may include drowsiness, bradycardia or tachycardia, dizziness, fainting, headache, nausea, mental/mood changes (e.g., agitation, confusion), insomnia, tremors, unusual sweating, and weakness.[21] In children, oxymetazoline overdose can cause profound central nervous system (CNS) depression, similar to clonidine, due to stimulation of central α2​-adrenergic and imidazoline receptors. This can lead to coma, bradycardia, respiratory depression, and hypotension.[3] Accidental ingestion by children has resulted in serious adverse events requiring hospitalization.[25] Severe adverse events reported with very high doses or misuse include cerebral vasospasms, stroke, and psychosis (particularly in individuals with a pre-existing psychiatric history).[19]
• Kovanaze Overdose: Overdose with Kovanaze involves potential toxicity from both oxymetazoline and tetracaine. Oxymetazoline-related effects are as described above. Tetracaine toxicity can manifest as rapid circulatory collapse, cardiac arrest, and CNS events such as seizures.[26]
• Management: There is no specific antidote for oxymetazoline overdose. Management is primarily supportive and symptomatic.
• Standard measures to remove unabsorbed drug (e.g., gastric lavage if ingestion is recent and significant, though often not recommended for imidazoline derivatives due to rapid CNS depression risk) should be considered cautiously.
• The pharmacological effects of oxymetazoline may be counteracted by α-adrenergic antagonists (e.g., phentolamine), although their use must be carefully considered.
• Benzodiazepines may be administered to manage seizures, convulsions, or severe anxiety, and may also help to lower blood pressure in cases of hypertensive crisis.[3]
• Close monitoring of vital signs, cardiovascular status, and respiratory function is essential.
• In case of suspected overdose or accidental ingestion, immediate medical attention should be sought, or a Poison Control Center contacted.[20]

Table 2: Summary of Common and Serious Adverse Effects of Oxymetazoline by Formulation/Route of Administration

Formulation/Route	Common Adverse Effects (Incidence if available)	Clinically Significant/Serious Adverse Effects	Key Source(s)
Nasal Spray (Decongestant) e.g., Afrin	Temporary burning, stinging, nasal dryness, sneezing, runny nose	Rebound congestion (rhinitis medicamentosa) with use >3-7 days, systemic effects (headache, dizziness, palpitations, hypertension), epistaxis, rare allergic reactions	2
Ophthalmic Solution (Ptosis - Upneeq 0.1%)	Punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain/irritation, headache (all 1-5%)	Potential for rebound hyperemia, dependence, or diminished effect over time; risk of increased intraocular pressure/angle-closure glaucoma	7
Ophthalmic Solution (Redness - Visine L.R. 0.025%)	Mild irritation	Overuse may increase eye redness; blurred vision, painful corneal irritation (less common)	47
Topical Cream (Rosacea - Rhofade 1%)	Application site reactions: dermatitis (2%), worsening rosacea lesions (1-3%), pruritus (1-2%), erythema (1-2%), pain (1-2%)	Local skin irritation	25
Combination Nasal Spray (Dental Anesthesia - Kovanaze)	Rhinorrhea, nasal congestion/discomfort, oropharyngeal pain, increased lacrimation (>10%)	Transient BP elevations, intranasal/pharyngeal hypoesthesia, epistaxis, dysphagia; Methemoglobinemia (rare but serious warning)	26

6. Drug Interactions

Oxymetazoline can participate in several clinically significant drug interactions, primarily pharmacodynamic in nature due to its adrenergic activity, but also with some potential for pharmacokinetic interactions.

Pharmacodynamic Interactions

These interactions stem from additive or antagonistic effects at adrenergic receptors or interference with adrenergic neurotransmission.

• Monoamine Oxidase Inhibitors (MAOIs): Concomitant use of oxymetazoline with MAOIs (or within 14 days of discontinuing an MAOI) is generally contraindicated or requires extreme caution. This combination can lead to a severe hypertensive crisis due to the potentiation of adrenergic effects, as MAOIs inhibit the breakdown of norepinephrine, and oxymetazoline also enhances sympathetic activity.[9] This is one of the most consistently highlighted and potentially dangerous interactions.
• Tricyclic Antidepressants (TCAs): TCAs can enhance the pressor effects of sympathomimetic amines like oxymetazoline, increasing the risk of hypertension and cardiac arrhythmias.[18]
• Beta-Adrenergic Antagonists (Beta-Blockers): The interaction with beta-blockers can be complex. If oxymetazoline is systemically absorbed, its α-adrenergic vasoconstrictive effects might become unopposed if β-mediated vasodilation is blocked, potentially leading to significant hypertension. Caution is advised, particularly with nonselective beta-blockers.[25]
• Alpha-Adrenergic Antagonists: Drugs such as prazosin, tamsulosin, or doxazosin (used for benign prostatic hyperplasia or hypertension) and phentolamine can antagonize the vasoconstrictive effects of oxymetazoline. This could lead to reduced efficacy of oxymetazoline or unpredictable blood pressure changes if systemic absorption of oxymetazoline occurs.[24]
• Other Sympathomimetic Agents: Co-administration with other sympathomimetics (e.g., pseudoephedrine, phenylephrine, epinephrine, amphetamine-like psychostimulants) can result in additive adrenergic effects, heightening the risk of cardiovascular side effects such as hypertension, tachycardia, and arrhythmias.[18] It is generally recommended to avoid the concomitant use of other oxymetazoline-containing products.[26]
• Anti-hypertensive Agents and Cardiac Glycosides: Oxymetazoline, through its α-adrenergic agonism, can impact blood pressure and may interfere with the efficacy of anti-hypertensive medications. Caution is also advised with cardiac glycosides like digoxin, as arrhythmias could be precipitated.[18]
• Ergot Alkaloids: Concurrent use with ergot alkaloids (e.g., ergotamine, methysergide), which also possess vasoconstrictive properties, can increase the risk of severe peripheral vasoconstriction and ergotism.[18]
• Antiparkinsonian Agents: Some antiparkinsonian agents, such as bromocriptine (which has dopaminergic and some α-adrenergic activity), may lead to additive cardiovascular toxicity when used with oxymetazoline.[18]
• Drugs Associated with Methemoglobinemia (with Kovanaze): The tetracaine component of Kovanaze can contribute to methemoglobinemia. The risk is increased if Kovanaze is used concurrently with other drugs known to cause methemoglobinemia, such as other local anesthetics (e.g., benzocaine, prilocaine), nitrates/nitrites, certain antineoplastic agents, antibiotics (e.g., dapsone, sulfonamides), antimalarials, some anticonvulsants, acetaminophen, metoclopramide, quinine, and sulfasalazine.[26]

The most clinically critical and consistently emphasized drug interactions for oxymetazoline are pharmacodynamic, particularly those involving MAOIs and other adrenergic agents, given the substantial risk of hypertensive crisis. Pharmacokinetic interactions, while theoretically possible, may be less of a concern for topical formulations that result in low systemic absorption, unless there is significant overuse or when formulations with higher systemic bioavailability (such as Kovanaze) are employed.

Pharmacokinetic Interactions

These interactions involve alterations in the absorption, distribution, metabolism, or excretion of oxymetazoline.

• UDP-glucuronosyltransferase 1A9 (UGT1A9) Interactions: Oxymetazoline is a substrate for UGT1A9.[29]
• Inhibitors of UGT1A9 (e.g., deferasirox, diflunisal, mefenamic acid, regorafenib, rifampin) could potentially increase plasma concentrations of oxymetazoline by reducing its glucuronidation.
• Competition for UGT1A9 with other substrates (e.g., acetaminophen, ibuprofen, valproic acid) is theoretically possible.
• Cytochrome P450 2C19 (CYP2C19) Interactions: Oxymetazoline is also a substrate for CYP2C19.[29]
• Inhibitors of CYP2C19 (e.g., fluconazole, fluoxetine, fluvoxamine, omeprazole, ticlopidine, voriconazole) may increase oxymetazoline plasma levels by inhibiting its oxidative metabolism.
• Inducers of CYP2C19 (e.g., carbamazepine, phenytoin, rifampin, St. John's Wort) could potentially decrease oxymetazoline plasma levels by enhancing its metabolism.

The interaction profile of Kovanaze is inherently more complex than that of oxymetazoline-only products due to the presence of tetracaine. This introduces additional considerations, such as interactions with drugs that affect the metabolism of ester-type local anesthetics (e.g., pseudocholinesterase inhibitors) and an increased risk of methemoglobinemia when co-administered with certain other drugs—concerns not typically associated with oxymetazoline when used alone.[26]

Table 3: Clinically Significant Drug Interactions with Oxymetazoline

Interacting Drug/Class	Mechanism of Interaction	Potential Clinical Consequence	Management/Recommendation	Formulation(s) Most Relevant To	Key Source(s)
Monoamine Oxidase Inhibitors (MAOIs)	Pharmacodynamic: Potentiation of adrenergic effects (reduced norepinephrine breakdown, increased release)	Severe hypertensive crisis, headache, hyperpyrexia	Avoid concurrent use (or within 14 days of MAOI discontinuation)	All formulations with potential systemic absorption	24
Tricyclic Antidepressants (TCAs)	Pharmacodynamic: Enhancement of pressor effects of oxymetazoline	Increased risk of hypertension, cardiac arrhythmias	Use with caution, monitor blood pressure	All formulations with potential systemic absorption	18
Beta-Adrenergic Antagonists (Beta-Blockers)	Pharmacodynamic: Potential for unopposed α-adrenergic effects (hypertension, bradycardia) if oxymetazoline is systemically absorbed	Hypertension, bradycardia	Use with caution, monitor blood pressure and heart rate	All formulations with potential systemic absorption	25
Other Sympathomimetics (e.g., pseudoephedrine, phenylephrine)	Pharmacodynamic: Additive adrenergic effects	Increased risk of hypertension, tachycardia, nervousness	Avoid concomitant use if possible, especially of other oxymetazoline products	All formulations	26
Alpha-Adrenergic Antagonists (e.g., prazosin, tamsulosin)	Pharmacodynamic: Antagonism of oxymetazoline's vasoconstrictive effects; potential for unpredictable BP changes	Reduced efficacy of oxymetazoline; hypotension or hypertension	Use with caution, monitor blood pressure	All formulations with potential systemic absorption	24
Ergot Alkaloids (e.g., ergotamine)	Pharmacodynamic: Additive vasoconstrictive effects	Increased risk of ergotism, severe peripheral vasoconstriction	Avoid concurrent use or use with extreme caution	All formulations with potential systemic absorption	18
CYP2C19 Inhibitors (e.g., fluconazole, omeprazole)	Pharmacokinetic: Decreased metabolism of oxymetazoline	Potentially increased oxymetazoline levels and side effects	Monitor for oxymetazoline toxicity if systemic exposure is high	Primarily formulations with higher systemic absorption (e.g., Kovanaze, or overuse of others)	29
CYP2C19 Inducers (e.g., rifampin, St. John's Wort)	Pharmacokinetic: Increased metabolism of oxymetazoline	Potentially decreased oxymetazoline levels and efficacy	Monitor for reduced efficacy if systemic exposure is relevant	Primarily formulations with higher systemic absorption	29
Drugs causing Methemoglobinemia (e.g., nitrates, sulfonamides, certain local anesthetics)	Pharmacodynamic (with tetracaine component): Additive risk	Increased risk of methemoglobinemia	Use with caution, monitor for signs of methemoglobinemia	Kovanaze	26

7. Use in Specific Populations

The safety and efficacy of oxymetazoline can be influenced by patient-specific factors such as age and physiological status (e.g., pregnancy, lactation).

7.1. Pregnancy and Lactation

Pregnancy:

• Oxymetazoline was previously assigned to FDA Pregnancy Category C, indicating that animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks. Under the current FDA labeling system, it is often listed as "Not Assigned".[3]
• There is a general lack of adequate and well-controlled studies on oxymetazoline use in pregnant women across its various formulations.[25]
• Animal Data:
• For Rhofade (topical cream), animal reproduction studies did not show adverse developmental effects at systemic exposures up to 3 times (rats) and 73 times (rabbits) the exposure associated with the maximum recommended human dose (MRHD). However, a case of fetal distress was reported following repeated intranasal use of an oxymetazoline-containing decongestant at a dose five times higher than recommended.[25]
• For Kovanaze (nasal spray), animal studies with oxymetazoline indicated structural abnormalities at high doses, while tetracaine alone did not show adverse developmental effects.[26]
• General animal studies have reported delayed skeletal ossification, increased pup mortality, and decreased pup weight at maternally toxic doses of oxymetazoline.[58]
• A theoretical association has been noted between renal collecting system anomalies in the fetus and maternal use of intranasal oxymetazoline during the second trimester.[58]
• For nasal spray formulations, some sources suggest that human studies have not definitively shown a risk of birth defects, but data are insufficient to completely rule out risk. Topical nasal application may be preferred over oral decongestants to minimize systemic exposure to the fetus. Short-term use (< 3 days) may be considered if the potential benefit justifies the potential risk, particularly during the second or third trimester.[59]
• The general recommendation is that oxymetazoline should be used during pregnancy only if clearly needed and the potential benefits outweigh the potential risks to the fetus. Consultation with a healthcare provider is essential.[21]

Lactation:

• It is generally unknown whether oxymetazoline is excreted into human breast milk following administration of most formulations.[25]
• Oxymetazoline has been detected in the milk of lactating animals (e.g., rats).[25]
• The potential effects of oxymetazoline on a nursing infant or on milk production are largely unknown.[25]
• The decision to use oxymetazoline during lactation should involve weighing the potential benefits to the mother against the potential risks to the nursing infant. Consultation with a healthcare provider is crucial.[21]

7.2. Pediatric Use

The use of oxymetazoline in children requires careful consideration due to potential increased sensitivity to its effects.

• Nasal Decongestants (e.g., Afrin):
• Generally not recommended for children younger than 6 years of age unless specifically advised by a physician.[21]
• Some product labels for lower concentrations (e.g., 0.025%) or specific pediatric formulations may allow use in children aged 2 to under 6 years, but only with adult supervision. The typical dose in this age group is 2-3 sprays or drops into each nostril every 10-12 hours, not to exceed two doses in a 24-hour period.[20] For children under 2 years of age, a doctor must be consulted.[20]
• Children may be more susceptible to systemic side effects, including profound CNS depression, from accidental ingestion or excessive absorption of oxymetazoline.[3] This heightened sensitivity is attributed to factors such as an immature blood-brain barrier and a different body surface area to weight ratio, potentially leading to greater systemic drug exposure per kilogram of body weight.
• The FDA advises against the use of over-the-counter cough and cold medicines in children younger than 2 years and recommends caution in children younger than 4 years.[55]
• Rhofade (1% Topical Cream): The safety and effectiveness of Rhofade have not been established in pediatric patients below the age of 18 years.[25]
• Upneeq (0.1% Ophthalmic Solution): The safety and efficacy of Upneeq have not been established in children younger than 13 years of age.[9] The FDA-approved prescribing information for Upneeq is primarily for adult use [24], and pediatric assessments under the Pediatric Research Equity Act (PREA) were required.[60]
• Kovanaze (Dental Anesthetic Nasal Spray): Kovanaze is indicated for use in children who weigh 40 kg or more.[26] It has not been studied in children under 3 years of age and is not advised for use in those weighing less than 40 kg due to a lack of demonstrated efficacy in this subgroup.[26] A 2018 FDA review of the Adverse Event Reporting System (FAERS) found no pediatric adverse event reports for Kovanaze at that time.[49]

7.3. Geriatric Use

The use of oxymetazoline in older adults warrants consideration of age-related physiological changes and potential comorbidities.

• Nasal Decongestants: General precautions for decongestant use apply, particularly if the elderly patient has co-existing conditions such as heart disease, hypertension, glaucoma, or diabetes, which are more prevalent in this age group.[55]
• Rhofade (1% Topical Cream): Clinical trials for Rhofade included subjects aged 65 years and older. Based on available data, no overall differences in safety or effectiveness were observed between these older subjects and younger subjects. However, the number of geriatric participants may have been insufficient to definitively conclude that responses are identical.[25]
• Upneeq (0.1% Ophthalmic Solution): Clinical trials for Upneeq did not reveal significant differences in safety or effectiveness between geriatric participants (≥65 years) and younger adults.[9]
• Kovanaze (Dental Anesthetic Nasal Spray): Clinical studies of Kovanaze did not include a sufficient number of patients aged 65 and over to determine if they respond differently from younger individuals. A trend towards a higher incidence of notable increases in systolic blood pressure was observed in dental patients older than 50 years of age. Elderly patients are more likely to have decreased renal, hepatic, or cardiac function and may be taking multiple medications, requiring caution and monitoring for signs of local anesthetic toxicity or exaggerated systemic effects of oxymetazoline.[26] The risk of methemoglobinemia associated with Kovanaze may also be increased in elderly patients.[61]

While clinical trial data for Rhofade and Upneeq suggest comparable efficacy and safety in geriatric patients, the specific findings for Kovanaze (a trend for higher blood pressure increases in those over 50 years) and overarching principles of geriatric pharmacology—such as polypharmacy, altered drug metabolism and excretion due to decreased organ function, and increased prevalence of comorbid conditions that are precautions for oxymetazoline use—indicate that a cautious and individualized approach is essential when prescribing or recommending oxymetazoline for older adults. The "no overall differences" observed in some trials might be limited by the sample size of geriatric participants, and the patient's overall clinical context remains paramount.

8. Regulatory Information and Marketed Products

FDA Approval History and Current Status

Oxymetazoline has a long history of use, with its regulatory status evolving over decades for various formulations and indications.

• Nasal Decongestant (e.g., Afrin): The oxymetazoline brand Afrin was first marketed as a prescription drug in 1966 and subsequently became available over-the-counter (OTC) in 1975.[2] Oxymetazoline hydrochloride is generally recognized as safe and effective (GRASE) for OTC use as a nasal decongestant. Some databases indicate a formal FDA approval date around 1986, which might pertain to a specific New Drug Application (NDA) or a consolidated regulatory action.[62]
• Rhofade (1% oxymetazoline HCl topical cream for rosacea): Received FDA approval on January 18, 2017. The application was submitted by Allergan plc (now part of AbbVie).[3]
• Upneeq (0.1% oxymetazoline HCl ophthalmic solution for acquired blepharoptosis): Granted FDA approval in July 2020. The NDA was submitted by RVL Pharmaceuticals in September 2019.[1]
• Kovanaze (tetracaine HCl and oxymetazoline HCl nasal spray for dental anesthesia): Approved by the FDA on June 29, 2016. The product was developed by St. Renatus, LLC.[26]
• Visine L.R. (0.025% oxymetazoline HCl ophthalmic solution for eye redness): This is a long-established OTC product. While the specific initial FDA approval date for this brand and indication for oxymetazoline is not detailed in the provided materials, its availability predates the approvals of Rhofade and Upneeq.

Major Brand Names

Oxymetazoline is marketed under numerous brand names globally, varying by formulation and indication.

• Nasal Decongestants: Afrin, Dristan 12-hour Nasal Spray, Mucinex Sinus-Max Nasal Spray, Nostrilla, Sinex Long-acting, Sudafed OM, Vicks Sinex, Zicam Sinus Relief, Zicam Extreme Congestion Relief, SinuFrin. International brands include Operil, Facimin, Nasivin, Logicin, and some formulations of Otrivin (though many Otrivin products contain xylometazoline, requiring careful distinction).[1]
• Rosacea (Topical Cream): Rhofade.[1]
• Acquired Blepharoptosis (Ophthalmic Solution): Upneeq. The investigational name STN1013800 was used during its development.[1]
• Ocular Redness (Ophthalmic Solution): Visine L.R., OcuClear.[2]
• Dental Anesthesia (Nasal Spray): Kovanaze.[1]

Key Manufacturers

The development and marketing of oxymetazoline products involve a range of pharmaceutical companies.

• Original Development: E. Merck Darmstadt.[2]
• Afrin: Historically associated with Schering-Plough, later Bayer HealthCare.[2]
• Rhofade: Developed and marketed by Allergan plc (now part of AbbVie).[3]
• Upneeq: Marketed by RVL Pharmaceuticals.[7]
• Kovanaze: Developed by St. Renatus, LLC.[26]
• Other major pharmaceutical companies involved in the broader nasal spray and related markets, some of whom may produce generic oxymetazoline products or similar therapeutic agents, include Johnson & Johnson, GlaxoSmithKline, Novartis, Sanofi, Pfizer, Reckitt Benckiser, Becton Dickinson & Company, AstraZeneca, Boehringer Ingelheim, and Viatris (formerly Mylan).[63]

The diverse array of companies participating in the oxymetazoline market—ranging from large, multinational corporations managing established OTC brands and newer prescription therapies, to smaller, more specialized firms driving niche innovations like Kovanaze and Upneeq—reflects a pharmaceutical market that is both mature and dynamic.[2] This landscape suggests that while the core molecule, oxymetazoline, has been available for decades, ongoing innovation in formulation technology, delivery systems, and the identification of new targeted indications continues to create commercial opportunities and expand its therapeutic utility. This demonstrates a continued belief in the value of this well-characterized molecule, adaptable for both incremental improvements in existing product lines and significant breakthroughs in addressing previously unmet medical needs.

Table 4: Overview of Marketed Oxymetazoline Formulations, Brand Names, and FDA-Approved Indications

Formulation Type	Common US Brand Name(s)	Oxymetazoline Concentration	Primary FDA-Approved Indication(s)	Initial US FDA Approval (Brand/Indication)	Key Manufacturer(s)
Nasal Spray/Drops (Decongestant)	Afrin, Vicks Sinex, Sudafed OM, Dristan, Nostrilla	0.05%, 0.025%	Nasal congestion due to cold, hay fever, allergies; Sinus congestion	OTC since 1975 (Afrin); specific generic approvals vary	Bayer, Kenvue, various generic mfrs.
Ophthalmic Solution (Acquired Blepharoptosis)	Upneeq	0.1%	Acquired blepharoptosis in adults	July 2020	RVL Pharmaceuticals
Topical Cream (Rosacea Erythema)	Rhofade	1%	Persistent facial erythema of rosacea in adults	January 18, 2017	Allergan (AbbVie)
Ophthalmic Solution (Ocular Redness)	Visine L.R., OcuClear	0.025%	Relief of redness of the eye due to minor eye irritations	Long-standing OTC (date not specified)	Johnson & Johnson Consumer Inc. (Visine)
Combination Nasal Spray (Dental Anesthesia)	Kovanaze	0.1 mg oxymetazoline HCl (with 6 mg tetracaine HCl) per 0.2 mL spray	Regional dental anesthesia for specific maxillary teeth in adults and children ≥40 kg	June 29, 2016	St. Renatus, LLC

9. Comparative Efficacy and Alternative Treatments (Brief Overview)

While oxymetazoline is effective for its approved indications, alternative treatments are available, and comparative efficacy is a relevant consideration.

Nasal Congestion:

• Versus Xylometazoline: A clinical study involving 30 healthy adults compared the decongestive effects of oxymetazoline and xylometazoline using active anterior rhinomanometry and acoustic rhinometry. Both were found to be fast-acting and potent topical decongestants with largely similar effects on nasal resistance, airflow, and cross-sectional areas of the nasal cavity. No statistically significant difference was observed between the two, except for one specific cross-sectional area measurement (CSA3).[65] Another literature review suggested that while both have low systemic exposure, xylometazoline might have a faster onset of action and a shorter duration of therapeutic effect compared to oxymetazoline.[66]
• Other Alternatives: Other pharmacological options for nasal congestion include oral decongestants (e.g., pseudoephedrine, phenylephrine), saline nasal sprays or irrigations (for moisturizing and clearing passages), and intranasal corticosteroids (particularly for allergic rhinitis and chronic rhinosinusitis, targeting inflammation).[11] Non-pharmacological approaches like humidifiers can also provide relief.

Persistent Facial Erythema of Rosacea:

• Versus Brimonidine: Both topical oxymetazoline (Rhofade) and topical brimonidine are FDA-approved α-adrenergic agonists for treating persistent facial erythema of rosacea. In their respective phase III clinical trials, both medications demonstrated efficacy by meeting the primary outcome of achieving at least a 2-grade decrease from baseline on both the Clinician Erythema Assessment (CEA) and the Subject Self-Assessment (SSA) scales when compared to vehicle controls. Treatment-related adverse events for both oxymetazoline and brimonidine are typically mild and localized to the application site.[41] The choice between these agents may depend on individual patient response, tolerability (including the incidence of rebound erythema, which has been reported with brimonidine and is a theoretical concern with oxymetazoline), patient preference, cost, and formulary availability, as clear superiority of one agent over the other for the approved indication has not been definitively established in head-to-head trials.
• Other Alternatives: Other topical treatments for rosacea target different aspects of the condition. For the papulopustular subtype, options include ivermectin, azelaic acid, metronidazole, and minocycline. Some of these may also have some effect on erythema. Non-pharmacological options like pulsed dye laser therapy can also be effective for erythema and telangiectasias.[11]

Acquired Blepharoptosis:

• Upneeq (oxymetazoline ophthalmic solution) is currently the only FDA-approved pharmacological (eye drop) treatment for acquired blepharoptosis.[7]
• Other Alternatives: The traditional mainstay of treatment for significant or symptomatic blepharoptosis has been surgical correction (e.g., Müller's muscle conjunctival resection, levator palpebrae superioris advancement or resection).[9] Other adrenergic agonist eye drops, such as phenylephrine and apraclonidine, have been used off-label or for diagnostic purposes to assess potential surgical outcomes by temporarily stimulating eyelid elevation. However, these agents have limitations for therapeutic use, including short duration of action, potential for systemic side effects (especially with phenylephrine), or lack of FDA approval for this indication.[7] Naphazoline has also shown some effect on eyelid elevation but carries a risk of tachyphylaxis with regular use.[7]

10. Recent Research and Future Perspectives

Research into oxymetazoline continues, exploring new therapeutic applications, optimizing existing uses, and further defining its pharmacological profile.

Summary of Ongoing and Recent Clinical Trials:

• Presbyopia: Oxymetazoline, as part of investigational ophthalmic formulations (e.g., AGN-190584, AGN-199201), has been evaluated in Phase 2 clinical trials for the treatment of presbyopia.[10] This line of research suggests an interest in its potential effects on pupillary constriction or ciliary muscle function to improve near vision.
• Eye Redness and Palpebral Fissure Height (Upneeq): Clinical trial NCT04831047 aimed to further evaluate the effects of Upneeq (0.1% oxymetazoline) on eye redness and palpebral fissure height, as well as patient-reported eye appearance.[12] While Upneeq is approved for ptosis, this study explores its cosmetic and functional effects on eye redness and eyelid position more broadly, including in individuals without significant ptosis. The study protocol notes that prior studies reported improvement in hyperemia with oxymetazoline in non-infectious conjunctivitis, and this trial sought to objectively assess effects on redness in healthy eyes.[12]
• Sleep Apnea: There is ongoing research investigating the potential role of oxymetazoline nasal spray, often as an adjunctive therapy, in improving symptoms for patients with mild obstructive sleep apnea.[11] The rationale is likely based on its ability to reduce nasal airway resistance.
• Pulpal Hemostasis and Antimicrobial Activity in Dentistry: Recent in vitro research has explored the off-label use of over-the-counter nasal solutions containing oxymetazoline (often with benzalkonium chloride, BKC, as a preservative) as a potential agent for dental pulp management following carious or traumatic exposure. Studies suggest that the oxymetazoline component can provide hemostasis via vasoconstriction, while the BKC component may offer antimicrobial activity against oral bacteria like Rothia dentocariosa and Streptococcus mutans.[51] NS-OXY was found to have superior antimicrobial effects against R. dentocariosa compared to 20% ferric sulfate, a standard pulpal management agent, and also demonstrated debris removal capabilities on dental surfaces.[51] This emerging area suggests a novel application for oxymetazoline-containing solutions in dental procedures.
• Combination Therapies for Nasal Congestion: Studies are investigating the use of oxymetazoline in combination with other medications, such as intranasal glucocorticosteroids, to potentially enhance efficacy in treating nasal congestion, particularly in chronic conditions.[11]
• Hypotension during Spinal Anesthesia: Oxymetazoline hydrochloride is being studied as a potential agent to prevent hypotension during spinal anesthesia, for example, in cesarean sections, when administered via intramuscular injection.[11] This explores a systemic vasoconstrictive role to counteract anesthesia-induced vasodilation.

Potential Future Directions:

The ongoing research highlights several potential future directions for oxymetazoline:

1. Expanded Ophthalmic Uses: Beyond ptosis and redness relief, the investigation into presbyopia treatment could open a significant new market if successful. Further studies on its effects on general eye appearance and cosmesis may also lead to broader applications.
2. Novel Dental Applications: The preliminary findings on pulpal hemostasis and antimicrobial activity are promising and could lead to the development of specialized dental formulations or protocols, offering an alternative to existing agents.
3. Optimized Combination Therapies: Combining oxymetazoline with other active ingredients, as seen with Kovanaze (tetracaine) and investigational combinations with corticosteroids, could yield synergistic effects and improved treatment outcomes for various conditions.
4. Systemic Applications (with caution): The trial for preventing hypotension during spinal anesthesia indicates an interest in controlled systemic uses, though this would require careful dose titration and patient selection due to the known cardiovascular effects of systemic sympathomimetics.
5. Refined Formulations and Delivery Systems: Continued innovation in drug delivery could lead to formulations that further enhance local effects while minimizing systemic absorption, potentially improving the safety profile for long-term or more frequent use in specific indications.

The long history of oxymetazoline, combined with its well-defined primary mechanism of action and the continued discovery of new applications, suggests that this "old" drug may yet offer new therapeutic possibilities. However, careful consideration of its safety profile, particularly regarding rebound effects and cardiovascular precautions, will remain paramount in any future development.

11. Conclusion

Oxymetazoline, an imidazole derivative and potent α-adrenergic agonist, has demonstrated remarkable therapeutic versatility since its development in 1961. Initially introduced as a nasal decongestant, its applications have significantly expanded to include the topical treatment of persistent facial erythema in rosacea (Rhofade), ophthalmic management of acquired blepharoptosis (Upneeq) and ocular redness (Visine L.R.), and as a vasoconstrictive adjuvant in a combination product for needle-free dental anesthesia (Kovanaze). This evolution highlights a successful paradigm of repurposing an established molecule by leveraging its core vasoconstrictive mechanism through targeted formulations and delivery systems.

The pharmacological profile of oxymetazoline is characterized by its direct agonism at α1​-adrenergic receptors and partial agonism at α2​-adrenergic receptors, leading to vasoconstriction in various tissues. Its lipophilic nature allows for rapid absorption and onset of local effects, but also necessitates caution regarding potential systemic absorption and associated sympathomimetic side effects, particularly with overuse or in susceptible populations. Pharmacokinetic studies reveal generally low systemic exposure with topical applications like Rhofade and Upneeq, though formulations like Kovanaze can result in higher peak plasma concentrations. Metabolism is minimal, with the drug primarily excreted unchanged.

Clinically, oxymetazoline has shown efficacy across its diverse indications. As a nasal decongestant, it provides rapid and prolonged relief. For rosacea, it reduces facial erythema. In ophthalmology, Upneeq significantly improves eyelid elevation in ptosis and can reduce ocular redness. Kovanaze effectively provides regional dental anesthesia. However, a consistent concern across topical mucosal applications (nasal and ophthalmic) is the risk of rebound phenomena with prolonged use, underscoring the importance of adherence to recommended treatment durations.

The safety profile of oxymetazoline is generally favorable when used as directed for its approved indications. Common adverse effects are typically localized and transient. However, systemic effects, particularly cardiovascular (e.g., hypertension, palpitations) and CNS effects (in cases of overdose or in sensitive pediatric populations), are important considerations. Significant drug interactions, especially with MAOIs and other adrenergic agents, can lead to severe hypertensive reactions.

Use in specific populations requires careful assessment. Pediatric use is often restricted or requires lower concentrations due to increased sensitivity. While geriatric patients have generally shown comparable responses for some formulations, underlying comorbidities and polypharmacy necessitate caution. Data on use during pregnancy and lactation are limited, advising a risk-benefit assessment.

Recent research continues to explore new avenues for oxymetazoline, including its potential in treating presbyopia, adjunctive use in sleep apnea, and novel applications in dental pulp management. The journey of oxymetazoline from a simple nasal spray to a multi-faceted therapeutic agent underscores the enduring value of well-characterized drugs and the potential for innovation through refined understanding of pharmacology and drug delivery. Future developments will likely focus on optimizing efficacy, minimizing side effects through advanced formulations, and further elucidating its role in emerging therapeutic areas, always balancing its potent vasoconstrictive benefits against its known safety considerations.

Works cited

1. Oxymetazoline: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed May 15, 2025, https://go.drugbank.com/drugs/DB00935
2. Oxymetazoline - Wikipedia, accessed May 15, 2025, https://en.wikipedia.org/wiki/Oxymetazoline
3. Oxymetazoline - New Drug Approvals, accessed May 15, 2025, https://newdrugapprovals.org/tag/oxymetazoline/
4. “A Comprehensive Review on Oxymetazoline Hydrochloride as Nasal Spray” - Journal of Emerging Technologies and Innovative Research, accessed May 15, 2025, https://www.jetir.org/papers/JETIR2412054.pdf
5. Oxymetazoline Hydrochloride Eye-Drops as Treatment for Myasthenia Gravis-Related Ptosis: A Description of Two Cases - PMC, accessed May 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10111874/
6. Efficacy and Safety of Oxymetazoline 1% Cream for the Treatment of ..., accessed May 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11959211/
7. AAO Report Concludes Oxymetazoline Effectively Treats Ptosis Short-term, accessed May 15, 2025, https://www.reviewofoptometry.com/news/article/aao-report-concludes-oxymetazoline-effectively-treats-ptosis-shortterm
8. Rhofade (oxymetazoline hydrochloride) FDA Approval History - Drugs.com, accessed May 15, 2025, https://www.drugs.com/history/rhofade.html
9. Oxymetazoline - EyeWiki, accessed May 15, 2025, https://eyewiki.org/Oxymetazoline
10. Oxymetazoline Completed Phase 2 Trials for Presbyopia Treatment | DrugBank Online, accessed May 15, 2025, https://go.drugbank.com/drugs/DB00935/clinical_trials?conditions=DBCOND0001183&phase=2&purpose=treatment&status=completed
11. Oxymetazoline Hydrochloride – Application in Therapy and Current Clinical Research, accessed May 15, 2025, https://clinicaltrials.eu/inn/oxymetazoline-hydrochloride/
12. The effect of Upneeq (oxymetazoline hydrochloride 0.1%) on palpebral fissure height, eye redness, and - ClinicalTrials.gov, accessed May 15, 2025, https://cdn.clinicaltrials.gov/large-docs/47/NCT04831047/Prot_SAP_000.pdf
13. oxymetazoline | Ligand page | IUPHAR/BPS Guide to ..., accessed May 15, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=124
14. Oxymetazoline hydrochloride | DrugBank Online, accessed May 15, 2025, https://go.drugbank.com/salts/DBSALT000821
15. SID 135650785 - PubChem, accessed May 15, 2025, https://pubchem.ncbi.nlm.nih.gov/substance/135650785
16. 6-(1,1-Dimethylethyl)-3-(1H-imidazol-2-ylmethyl)-2,4-dimethylphenol - PubChem, accessed May 15, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Oxymetazoline-metabolite-M2
17. Oxymetazoline Hydrochloride (EENT) Monograph for Professionals - Drugs.com, accessed May 15, 2025, https://www.drugs.com/monograph/oxymetazoline-hydrochloride-eent.html
18. Oxymetazoline : Indications, Uses, Dosage, Drugs Interactions, Side effects, accessed May 15, 2025, https://medicaldialogues.in/generics/oxymetazoline-2723659
19. Oxymetazoline - Alzheimer's Drug Discovery Foundation, accessed May 15, 2025, https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Oxymetazoline.pdf
20. CHILDREN AFRIN EXTRA MOISTURIZING STUFFY NOSE PUMP MIST STUFFY NOSE PUMP MIST- oxymetazoline hydrochloride spray, metere... - CHILDREN AFRIN EXTRA MOISTURIZING STUFFY NOSE PUMP MIST STUFFY NOSE PUMP MIST- oxymetazoline hydrochloride spray, metered - DailyMed, accessed May 15, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e3b239bd-ffc7-600c-e053-2a95a90a3b3b
21. Oxymetazoline Nasal Spray: MedlinePlus Drug Information, accessed May 15, 2025, https://medlineplus.gov/druginfo/meds/a608026.html
22. Oxymetazoline HCl Nasal solution, USP - Medline, accessed May 15, 2025, https://www.medline.com/media/catalog/Docs/MSDS/MSD_SDSD97614.pdf
23. Upneeq (oxymetazoline): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing, accessed May 15, 2025, https://www.webmd.com/drugs/2/drug-179884/upneeq-pf-ophthalmic-eye/details
24. NDA 212520 Page 4 - accessdata.fda.gov, accessed May 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/0212520s000lbl.pdf
25. www.accessdata.fda.gov, accessed May 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf
26. KOVANAZE- tetracaine hydrochloride and ... - DailyMed, accessed May 15, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2af5404-3cfe-445d-8328-19e667ecdc43
27. Rapid and Sustained Eyelid Elevation in Acquired Blepharoptosis ..., accessed May 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8240850/
28. Intranasal tetracaine and oxymetazoline: a newly approved drug ..., accessed May 15, 2025, https://pubmed.ncbi.nlm.nih.gov/27646144/
29. Showing BioInteractions for Oxymetazoline (DB00935) | DrugBank ..., accessed May 15, 2025, https://go.drugbank.com/drugs/DB00935/biointeractions
30. Topical nasal decongestant oxymetazoline (0.05%) provides relief of ..., accessed May 15, 2025, https://pubmed.ncbi.nlm.nih.gov/29785414/
31. Upneeq: Prescription Eye Drop for Low-Lying Lids, accessed May 15, 2025, https://www.upneeq.com/
32. Oxymetazoline nasal (Afrin, Sinex, and others) - Uses, Side Effects, and More - WebMD, accessed May 15, 2025, https://www.webmd.com/drugs/2/drug-12305/afrin-sinus-oxymetazoline-nasal/details
33. Oxymetazoline nasal Uses, Side Effects & Warnings - Drugs.com, accessed May 15, 2025, https://www.drugs.com/mtm/oxymetazoline-nasal.html
34. Oxymetazoline nasal spray three times daily for four weeks in ..., accessed May 15, 2025, https://pubmed.ncbi.nlm.nih.gov/14579657/
35. Oxymetazoline (Afrin) Nasal Spray - Cleveland Clinic, accessed May 15, 2025, https://my.clevelandclinic.org/health/drugs/18562-oxymetazoline-nasal-spray
36. What Is Oxymetazoline Nasal Spray & What Is It Used For? | SUDAFED®, accessed May 15, 2025, https://www.sudafed.com/know-your-congestion/what-is-oxymetazoline
37. www.rhofade.com, accessed May 15, 2025, https://www.rhofade.com/
38. Oxymetazoline Topical: MedlinePlus Drug Information, accessed May 15, 2025, https://medlineplus.gov/druginfo/meds/a617018.html
39. Early investigational agents for the treatment of rosacea: drugs in phase I and II clinical development - Taylor & Francis Online, accessed May 15, 2025, https://www.tandfonline.com/doi/full/10.1080/13543784.2025.2463093?src=exp-la
40. Oxymetazoline (Topical): Rosacea - PMC - PubMed Central, accessed May 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3839519/
41. Difference in vasoconstrictors: oxymetazoline vs. brimonidine - PubMed, accessed May 15, 2025, https://pubmed.ncbi.nlm.nih.gov/31294643/
42. Oxymetazoline Cream: Package Insert / Prescribing Info - Drugs.com, accessed May 15, 2025, https://www.drugs.com/pro/oxymetazoline-cream.html
43. Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% - Alabama Family Eye Care, accessed May 15, 2025, https://www.alfamilyeyes.com/wp-content/uploads/2022/03/Upneeq-brochure.pdf
44. Oxymetazoline - brand name list from Drugs.com, accessed May 15, 2025, https://www.drugs.com/ingredient/oxymetazoline.html
45. The first and only FDA-approved, prescription eye drop that lifts low-lying eyelids (acquired ptosis) in adults - Upneeq, accessed May 15, 2025, https://ecp.upneeq.com/wp-content/uploads/2024/11/PM-US-UPN-1603-New-Patient-Brochure.pdf
46. The effects of topical oxymetazoline on eyelid position, eye redness ..., accessed May 15, 2025, https://pubmed.ncbi.nlm.nih.gov/36996503/
47. Visine L.R.: Package Insert / Prescribing Information - Drugs.com, accessed May 15, 2025, https://www.drugs.com/pro/visine-l-r.html
48. Oxymetazoline in the treatment of allergic and non-infectious ..., accessed May 15, 2025, https://pubmed.ncbi.nlm.nih.gov/391626/
49. Kovanaze (tetracaine HCl and oxymetazoline HCl) Nasal Spray - FDA, accessed May 15, 2025, https://www.fda.gov/media/116018/download
50. Safety and Efficacy of a Novel Nasal Spray for Maxillary Dental Anesthesia - ResearchGate, accessed May 15, 2025, https://www.researchgate.net/publication/236924562_Safety_and_Efficacy_of_a_Novel_Nasal_Spray_for_Maxillary_Dental_Anesthesia
51. The use of oxymetazoline-based nasal solutions to remove bacteria-blood debris and eradicate Rothia dentocariosa: an artificial cavity model study, accessed May 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11951828/
52. An Oxymetazoline-Based Nasal Solution Removes Bacteria–Blood Debris on Dental Surfaces and Has Antimicrobial Activity Toward Streptococcus mutans - PMC, accessed May 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11818354/
53. Oxymetazoline Nasal: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing, accessed May 15, 2025, https://www.webmd.com/drugs/2/drug-1352-214/oxymetazoline-nasal/decongestant-drops-nasal/details
54. Oxymetazoline Nasal: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing, accessed May 15, 2025, https://www.webmd.com/drugs/2/drug-1352-9214/oxymetazoline-nasal/decongestant-spray-nasal/details
55. Decongestants | Senior Health Services | Hartford HealthCare | CT, accessed May 15, 2025, https://hhcseniorservices.org/health-wellness/health-resources/health-library/detail?id=sig48021&lang=en-us
56. Oxymetazoline (ophthalmic route) - Mayo Clinic, accessed May 15, 2025, https://www.mayoclinic.org/drugs-supplements/oxymetazoline-ophthalmic-route/description/drg-20065237
57. Oxymetazoline (topical application route) - Mayo Clinic, accessed May 15, 2025, https://www.mayoclinic.org/drugs-supplements/oxymetazoline-topical-application-route/description/drg-20406026
58. Oxymetazoline topical (Rhofade) Use During Pregnancy - Drugs.com, accessed May 15, 2025, https://www.drugs.com/pregnancy/oxymetazoline-topical.html
59. Management of Cold and Flu During Pregnancy | InfantRisk Center, accessed May 15, 2025, https://infantrisk.com/content/management-cold-and-flu-during-pregnancy
60. UPNEEQ (oxymetazoline hydrochloride ophthalmic solution) - accessdata.fda.gov, accessed May 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/212520Orig1s000ltr.pdf
61. Tetracaine and oxymetazoline (nasal route) - Mayo Clinic, accessed May 15, 2025, https://www.mayoclinic.org/drugs-supplements/tetracaine-and-oxymetazoline-nasal-route/description/drg-20312343
62. Oxymetazoline Hydrochloride | C16H25ClN2O | CID 66259 - PubChem, accessed May 15, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/66259
63. Oxymetazoline Market: future outlook and trends 2032 - WiseGuy Reports, accessed May 15, 2025, https://www.wiseguyreports.com/reports/oxymetazoline-market
64. Global Nasal Sprays Market Poised for Significant Growth, - GlobeNewswire, accessed May 15, 2025, https://www.globenewswire.com/news-release/2025/03/03/3035394/0/en/Global-Nasal-Sprays-Market-Poised-for-Significant-Growth-Expected-to-Reach-USD-28-345-5-Million-by-2035-grow-at-a-CAGR-of-6-0-Future-Market-Insights-Inc.html
65. A comparative analysis of the decongestive effect of oxymetazoline and xylometazoline in healthy subjects - PubMed, accessed May 15, 2025, https://pubmed.ncbi.nlm.nih.gov/21069518/
66. Pharmacokinetics and Pharmacodynamics of Topical Decongestants Xylometazoline and Oxymetazoline: A Literature Review - ResearchGate, accessed May 15, 2025, https://www.researchgate.net/publication/375439969_Pharmacokinetics_and_Pharmacodynamics_of_Topical_Decongestants_Xylometazoline_and_Oxymetazoline_A_Literature_Review
67. Treatment of Allergic Rhinitis and Allergic Conjunctivitis | The Medical Letter Inc., accessed May 15, 2025, https://secure.medicalletter.org/TML-article-1725a
68. A real-world study of quality of life following treatment with xylometazoline hydrochloride in individuals with common cold - PubMed, accessed May 15, 2025, https://pubmed.ncbi.nlm.nih.gov/38372128/
69. Efficacy of widely used topical drugs for rosacea: a systematic review and meta-analysis, accessed May 15, 2025, https://pubmed.ncbi.nlm.nih.gov/40246142/